Mesenchymal stem cells as tool for antitumor therapy

Karshieva, Saida Sh; Krasikova, L. S.; Belyavskii, A. V.

doi:10.1134/s0026893313010068

Cited by 3 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hydrochloric acid is added to a fixed amount of magnetite bearing erythrocytes and contents are heated at 600 degrees C for 2hr.Then 20% w/v trichloro-acetic acid is added and supernatant obtained after centrifugation is used to determine magnetite concentration using atomic absorption spectroscopy. 27 Shelf life, Stability and Cross linking of Released Erythrocytes: Glutaraldehyde (0.2%) treated erythrocytes in a sintered glass funnel (G-4) are collected by filtration and dried in vacuum (200mm Hg) for 10hr.Alternatively the erythrocyte suspension is filled into vials and lyophilized at -400 degree C to 0.01 torr using a laboratory lyophilizer. The dried powder is filled in amber colour glass vials and stored at 40 degree C for a month.…”

Section: Entrapped Magnitude Studymentioning

confidence: 99%

An Advanced Review on Resealed Erythrocytes

Begum

Mustafa

2019

Asian J Pharm Res Dev

View full text Add to dashboard Cite

Now a days there are numerous applications have been proposed for the use of resealed erythrocytes as carrier for drugs, enzyme replacement therapy etc. Until other carrier systems come of age, resealed erythrocytes technology will remain an active field for the further research. The use of resealed erythrocytes shows potential for a safe and effective delivery of various bioactive molecules for effective targeting. In coming future, erythrocyte based drug delivery system with their capability to afford controlled and site specific drug delivery have been developed for disease management. Erythrocyte carriers are “Nano devices in the field of Nanotechnology”. A large amount of valuable work is needed so as to utilize the potentials of erythrocytes in passive as well as active targeting of drugs in diseases like cancer. At present erythrocytes are most effective carriers in novel drug delivery systems considering their tremendous potential. Hence the present article is reviewed about method of drug loading, evaluation and applications of RSE.

show abstract

Section: Entrapped Magnitude Studymentioning

confidence: 99%

An Advanced Review on Resealed Erythrocytes

Begum

Mustafa

2019

Asian J Pharm Res Dev

View full text Add to dashboard Cite

show abstract

“…A major advantage of using MSCs for stem cell therapies is the ease at which they can be manipulated, either through changes in culture conditions or virally mediated genetic engineering. Lentivirus- and retrovirus-based delivery systems are efficient and are capable of integrating into the genome ensuring the long-term expression of the transgene [ 70 ]. Retroviral transfection of the deficient IL-2 receptor γ (IL2RG) in autologous hematopoietic stem cells, ex vivo , has been clinically utilized in the treatment of X-linked severe combined immunodeficiency (SCID) [ 71 ] and the treatment of other diseases [ 72 ].…”

Section: Genetic Delivery Using Mscsmentioning

confidence: 99%

Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases

Wyse

Dunbar

Rossignol

2014

IJMS

View full text Add to dashboard Cite

The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants have been shown to be safe in a variety of applications, in addition to recent findings that MSCs have useful immunomodulatory and chemotactic properties, the use of these cells as vehicles for delivering or producing beneficial proteins for therapeutic purposes has been the focus of several labs. In our lab, the use of genetic modified MSCs to release neurotrophic factors for the treatment of neurodegenerative diseases is of particular interest. Specifically, glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic factors for Parkinson’s, Alzheimer’s and Huntington’s diseases, respectively. The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs.

show abstract

Gene therapy in pancreatic cancer

Liu¹

2014

WJG

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a highly lethal disease and notoriously difficult to treat. Only a small proportion of PC patients are eligible for surgical resection, whilst conventional chemoradiotherapy only has a modest effect with substantial toxicity. Gene therapy has become a new widely investigated therapeutic approach for PC. This article reviews the basic rationale, gene delivery methods, therapeutic targets and developments of laboratory research and clinical trials in gene therapy of PC by searching the literature published in English using the PubMed database and analyzing clinical trials registered on the Gene Therapy Clinical Trials Worldwide website (http://www. wiley.co.uk/genmed/ clinical). Viral vectors are main gene delivery tools in gene therapy of cancer, and especially, oncolytic virus shows brighter prospect due to its tumor-targeting property. Efficient therapeutic targets for gene therapy include tumor suppressor gene p53, mutant oncogene K-ras, anti-angiogenesis gene VEGFR, suicide gene HSK-TK, cytosine deaminase and cytochrome p450, multiple cytokine genes and so on. Combining different targets or combination strategies with traditional chemoradiotherapy may be a more effective approach to improve the efficacy of cancer gene therapy. Cancer gene therapy is not yet applied in clinical practice, but basic and clinical studies have demonstrated its safety and clinical benefits. Gene therapy will be a new and promising field for the treatment of PC.

show abstract

Mesenchymal stem cells as tool for antitumor therapy

Cited by 3 publications

References 92 publications

An Advanced Review on Resealed Erythrocytes

An Advanced Review on Resealed Erythrocytes

Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases

Gene therapy in pancreatic cancer

Contact Info

Product

Resources

About